Category

News
This article was originally posted on DocwireNews ABSTRACT INTRODUCTION: : Smoldering multiple myeloma (SMM) is a clonal plasma cell (PC) disorder considered a prelude to MM due to its greater malignant potential compared to monoclonal gammopathy of undetermined significance (MGUS). Despite tectonic changes in the SMM landscape that occurred since it was first distinguished four...
Continue Reading
This article was originally posted on Docwirenews According to new data published in Blood, patients with multiple myeloma (MM) who are hospitalized for COVID-19 infection face higher mortality compared with patients without MM, with age, disease status, and renal involvement serving as predictors of worse outcomes. MM is a hematological cancer of the plasma cells, particularly within bone...
Continue Reading
This article was originally published on Cancer Network Treatment options for multiple myeloma only continued to improve over the course of 2020, even with the development of the coronavirus disease 2019 (COVID-19) pandemic. Advancements such as the approval of selinexor (Xpovio) in combination with bortezomib (Velcade) and dexathamethasone for the treatment of adults with multiple myeloma who...
Continue Reading
This article was originally published on UrbanhealthToday Insurance status was found to be significantly associated with survival for patients with multiple myeloma (MM), according to a study presented at the 2020 American Society of Hematology Annual Meeting & Exposition. Researchers analyzed data from the 2007-2016 Surveillance, Epidemiology, and End Results (SEER) Program database and identified 41,846 adults...
Continue Reading
This article was originally published on Curetoday The last 15 years have proved pivotal for patients with myeloma, as the Food and Drug Administration (FDA) has approved many active and highly specific therapies to treat the disease, according to Dr. Giada Bianchi. Bianchi, who is an associate director of the Amyloidosis Program at Brigham and...
Continue Reading
This article was originally published Cure There has been tremendous growth over the years in terms of treatment options for patients with multiple myeloma. That growth has extended to patients in the relapsed and refractory setting who often face an even more complex disease than patients with traditional multiple myeloma. This is as a result...
Continue Reading
This article was originally published on The limbic Subcutaneous daratumumab with pomalidomide and dexamethasone (D-Pd) is an effective and convenient treatment for patients with relapsed or refractory multiple myeloma who have received at least one line of therapy, including lenalidomide and a proteasome inhibitor. Speaking at the 62nd ASH Annual Meeting, Professor Meletios Dimopoulos presented...
Continue Reading
This article was originally published on Ash Clinical News Patients with relapsed/refractory multiple myeloma (MM) who were treated with a combination of subcutaneous daratumumab plus pomalidomide-dexamethasone (Pd) had a 37% lower risk of disease progression or death, compared with those who received Pd alone, according to results from the phase III APOLLO trial. Meletios Dimopoulos, MD, from...
Continue Reading
This article was originally posted on MEDpage Today Despite some concern over a novel ocular toxicity, the FDA granted accelerated approval to belantamab mafodotin (Blenrep) for heavily pretreated multiple myeloma following backing from an advisory panel, the first approved therapy that targets the B-cell maturation antigen (BCMA). Belantamab mafodotin is indicated for patients that have failed a...
Continue Reading
Welcome to issue 36 of Multiple Myeloma Research Review. The use of ixazomib-based induction therapy in routine clinical practice is relatively uncommon for several reasons, so the first study for this issue is useful, as it describes the effectiveness and safety of such treatment in a multicentre cohort of real-world patients. US research has confirmed...
Continue Reading
1 2 3 29

Floor 7, 90 The Terrace
Wellington Central
New Zealand